Carta Valentina, Mangeri Lucia, Tiecco Giorgio, Focà Emanuele, Quiros-Roldan Eugenia, De Francesco Maria Antonia
Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Brescia, Italy.
Department of Clinical and Experimental Sciences, University of Brescia-ASST Spedali Civili, Brescia, Italy.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2341456. doi: 10.1080/21645515.2024.2341456. Epub 2024 Apr 22.
Few papers focus their attention on VZV vaccination effectiveness among people living with HIV (PLWH). Flanking the live attenuated vaccine (VZL) available, a newly recombinant vaccine (RZV) was recently introduced and approved for HZ prevention among adults. PLWH represents a population on which a particular attention should be applied, in order to guarantee the vaccine efficacy and safety. We performed a literature search in USNLM, PubMed, PubMed Central, PMC and Cochrane Library. From all the publications found eligible, data were extracted and processed per population, vaccine type, immunogenicity and ADRs. The review of the 13 included studies shows that both RZV and VZL are immunogenic and have an acceptable safety profile in adults and children living with HIV. However, given the lack of research available about vaccine efficacy in preventing VZV and HZ in PLWH, additional studies need to be performed, in order to achieve a full completeness of data.
很少有论文关注艾滋病毒感染者（PLWH）中水痘带状疱疹病毒（VZV）疫苗的有效性。在现有的减毒活疫苗（VZL）之外，一种新的重组疫苗（RZV）最近被引入并被批准用于预防成人带状疱疹（HZ）。PLWH是一个需要特别关注的人群，以确保疫苗的有效性和安全性。我们在美国国立医学图书馆（USNLM）、PubMed、PubMed Central、PMC和考科蓝图书馆进行了文献检索。从所有符合条件的出版物中，按人群、疫苗类型、免疫原性和不良反应（ADR）提取并处理数据。对纳入的13项研究的综述表明，RZV和VZL在艾滋病毒感染的成人和儿童中都具有免疫原性，并且安全性良好。然而，鉴于缺乏关于疫苗在预防PLWH中VZV和HZ方面疗效的研究，需要进行更多的研究，以实现数据的完全完整性。
